Hemolytic anemia
MONDO:0003664Anemia resulting from the premature destruction of the peripheral blood red cells. It may be congenital or it may be caused by infections, medications, or malignancies.
Also known as: anaemia hemolytic, anemia hemolytic, anemia, hemolytic, hemolytic anemia
188 clinical trials for this condition and its sub-types, 19 tagged with Hemolytic anemia itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
Sub-types of Hemolytic anemia
-
Paroxysmal nocturnal hemoglobinuria 73 trials
2 sub-types
- Paroxysmal nocturnal hemoglobinuria 1 0 trials
- Paroxysmal nocturnal hemoglobinuria 2 0 trials
-
Autoimmune hemolytic anemia 49 trials · 72 incl. sub-types
7 sub-types
- Autoimmune hemolytic anemia, warm type 29 trials
- Evans syndrome 19 trials
- Autoimmune hemolytic anemia, cold type 2 trials · 15 incl. sub-types Sub-types →
- Mixed-type autoimmune hemolytic anemia 1 trial
- Drug-induced autoimmune hemolytic anemia 0 trials
- Giant cell hepatitis with autoimmune hemolytic anemia 0 trials
- Neonatal autoimmune hemolytic anemia 0 trials
-
Familial hemolytic anemia 4 trials · 27 incl. sub-types
23 sub-types
- Congenital nonspherocytic hemolytic anemia 1 trial · 12 incl. sub-types Sub-types →
- Congenital dyserythropoietic anemia 4 trials · 5 incl. sub-types Sub-types →
- Abetalipoproteinemia 2 trials
- Cutaneous porphyria 2 trials
- Hereditary spherocytosis 2 trials Sub-types →
- Southeast Asian ovalocytosis 2 trials
- Glycogen storage disease VII 1 trial
- Glycogen storage disease due to aldolase A deficiency 1 trial
- Rh deficiency syndrome 0 trials
- X-linked congenital hemolytic anemia 0 trials
- Cryohydrocytosis 0 trials
- Dehydrated hereditary stomatocytosis 2 0 trials
- Dehydrated hereditary stomatocytosis with or without pseudohyperkalemia and/or perinatal edema 0 trials
- Elliptocytosis 1 0 trials
- Elliptocytosis 2 0 trials
- Familial pseudohyperkalemia 0 trials
- Hemolytic anemia due to diphosphoglycerate mutase deficiency 0 trials
- Hemolytic disease of fetus and newborn, RH-induced 0 trials
- Hereditary cryohydrocytosis with reduced stomatin 0 trials
- Overhydrated hereditary stomatocytosis 0 trials
- Primary CD59 deficiency 0 trials
- Renal tubular acidosis, distal, 4, with hemolytic anemia 0 trials
- Triosephosphate isomerase deficiency 0 trials
-
Hereditary stomatocytosis 1 trial · 3 incl. sub-types
7 sub-types
- Southeast Asian ovalocytosis 2 trials
- Rh deficiency syndrome 0 trials
- Cryohydrocytosis 0 trials
- Dehydrated hereditary stomatocytosis 0 trials Sub-types →
- Familial pseudohyperkalemia 0 trials
- Hereditary cryohydrocytosis with reduced stomatin 0 trials
- Overhydrated hereditary stomatocytosis 0 trials
-
Hereditary elliptocytosis 0 trials · 2 incl. sub-types
5 sub-types
- Southeast Asian ovalocytosis 2 trials
- Elliptocytosis 1 0 trials
- Elliptocytosis 2 0 trials
- Elliptocytosis 3 0 trials
- Hemolytic anemia with thermal sensitivity of red cells 0 trials
-
Non-autoimmune hemolytic anemia 1 trial
-
Heinz body anemia 0 trials
Most studied deeper sub-types
-
Could a daily pill help kids with rare blood disorder?
Disease control OngoingThis study tests a drug called mitapivat in children aged 1 to 18 with pyruvate kinase deficiency, a rare genetic condition that causes red blood cells to break down too quickly, leading to anemia. The trial compares mitapivat to a placebo to see if it can raise hemoglobin levels…
Phase 3 • Sponsor: Agios Pharmaceuticals, Inc. • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
Could a pill replace blood transfusions for kids with rare anemia?
Disease control OngoingThis phase 3 trial tests the drug mitapivat in children aged 1 to 18 with pyruvate kinase deficiency, a rare genetic disorder that causes red blood cells to break down too quickly. These children need regular blood transfusions. The study compares mitapivat to a placebo to see if…
Phase 3 • Sponsor: Agios Pharmaceuticals, Inc. • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
Lifeline drug mitapivat keeps flowing for rare blood disorder patients
Disease control By invitation onlyThis study offers continued access to the drug mitapivat for adults with pyruvate kinase deficiency who completed an earlier Agios-sponsored trial and cannot get the drug commercially. Only 6 participants are enrolled, and the main goal is to monitor side effects. The study does …
Phase 4 • Sponsor: Agios Pharmaceuticals, Inc. • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Sickle cell drug mitapivat faces Long-Term safety check in small study
Disease control OngoingThis study looks at the long-term safety and tolerability of the drug mitapivat in adults with stable sickle cell disease. Participants, who previously benefited from mitapivat in an earlier study, take the drug twice daily for up to 48 weeks, with an option to continue for anoth…
Phase 1/2 • Sponsor: National Heart, Lung, and Blood Institute (NHLBI) • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
New pill could slash sickle cell pain crises
Disease control OngoingThis large Phase 3 trial is testing an oral drug called etavopivat in 450 people with sickle cell disease. The goal is to see if taking a pill once daily can raise hemoglobin levels and reduce the number of painful vaso-occlusive crises compared to a placebo. Participants must ha…
Phase 3 • Sponsor: Forma Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC